Literature DB >> 20714343

Treating prostate cancer with radiotherapy.

Anna Wilkins1, Chris Parker.   

Abstract

This Review focuses on the adverse effects of radical radiotherapy for localized prostate cancer. The adverse effects are described in the context of alternative treatment modalities. First, we consider the methodological issues that make comparison between the different treatment modalities problematic. Such issues include differences in baseline levels of urinary, bowel and sexual dysfunction, the importance of using patient-reported outcomes and the distinction between actuarial and prevalence rates of treatment-related toxic effects. Second, we describe the pattern of adverse effects that occur over time after radiotherapy. Here, we focus on evidence for a beneficial effect of radiotherapy on some urinary symptoms, and the controversy regarding the risk of secondary malignancy. Third, predictors of radiation toxicity are discussed. Accurate prediction of radiotherapy toxicity would be an invaluable tool for treatment individualization. It is noteworthy that the data on the adverse effects of prostate radiotherapy necessarily relate to treatment as it was delivered in the past. It is likely that recent technical advances, such as intensity modulation and image guidance, will further improve the toxicity profile of prostate radiotherapy.

Entities:  

Mesh:

Year:  2010        PMID: 20714343     DOI: 10.1038/nrclinonc.2010.135

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  34 in total

1.  Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.

Authors:  David Christie; James Denham; Allison Steigler; David Lamb; Sandra Turner; Hedy Mameghan; David Joseph; John Matthews; Ian Franklin; Chris Atkinson; John North; Michael Poulsen; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Gillian Duchesne; Olga Kovacev; Lynne Francis; Andrew Kramar; Cate D'Este; Dana Bill
Journal:  Radiother Oncol       Date:  2005-11-04       Impact factor: 6.280

2.  Non-parametric methods for analysing recurrent complications of varying severity.

Authors:  R Lancar; A Kramar; C Haie-Meder
Journal:  Stat Med       Date:  1995-12-30       Impact factor: 2.373

3.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Authors:  M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

4.  Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma.

Authors:  A I Neugut; H Ahsan; E Robinson; R D Ennis
Journal:  Cancer       Date:  1997-04-15       Impact factor: 6.860

5.  Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years.

Authors:  Graça M Dores; Catherine Metayer; Rochelle E Curtis; Charles F Lynch; E Aileen Clarke; Bengt Glimelius; Hans Storm; Eero Pukkala; Flora E van Leeuwen; Eric J Holowaty; Michael Andersson; Tom Wiklund; Timo Joensuu; Mars B van't Veer; Marilyn Stovall; Mary Gospodarowicz; Lois B Travis
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

6.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

7.  A cost-outcome analysis of Image-Guided Patient Repositioning in the radiation treatment of cancer of the prostate.

Authors:  Nicolas Ploquin; Peter Dunscombe
Journal:  Radiother Oncol       Date:  2009-05-04       Impact factor: 6.280

Review 8.  Radiation-induced second cancers: the impact of 3D-CRT and IMRT.

Authors:  Eric J Hall; Cheng-Shie Wuu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

9.  Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT.

Authors:  Hans T Chung; Ping Xia; Linda W Chan; Eileen Park-Somers; Mack Roach
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-22       Impact factor: 7.038

10.  The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397).

Authors:  David P Dearnaley; Matthew R Sydes; Ruth E Langley; John D Graham; Robert A Huddart; Isabel Syndikus; John H L Matthews; Christopher D Scrase; Chakiath C Jose; John Logue; Richard J Stephens
Journal:  Radiother Oncol       Date:  2007-03-27       Impact factor: 6.280

View more
  8 in total

1.  Targeted therapies: An important piece of the localized prostate cancer puzzle?

Authors:  James W Denham
Journal:  Nat Rev Clin Oncol       Date:  2011-08-16       Impact factor: 66.675

2.  Impact of different setup approaches in image-guided radiotherapy as primary treatment for prostate cancer: a study of 2940 setup deviations in 980 MVCTs.

Authors:  Kilian Schiller; Alessia Petrucci; Hans Geinitz; Tibor Schuster; Hanno Specht; Severin Kampfer; Marciana Nona Duma
Journal:  Strahlenther Onkol       Date:  2014-04-23       Impact factor: 3.621

Review 3.  Racial Disparities in Sexual Dysfunction Outcomes After Prostate Cancer Treatment: Myth or Reality?

Authors:  Arthur L Burnett
Journal:  J Racial Ethn Health Disparities       Date:  2015-05-28

4.  Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.

Authors:  Rong Wang; Amer M Zeidan; James B Yu; Pamela R Soulos; Amy J Davidoff; Steven D Gore; Scott F Huntington; Cary P Gross; Xiaomei Ma
Journal:  Prostate       Date:  2016-11-21       Impact factor: 4.104

5.  An expression signature at diagnosis to estimate prostate cancer patients' overall survival.

Authors:  Z Peng; L Skoog; H Hellborg; G Jonstam; I-L Wingmo; M Hjälm-Eriksson; U Harmenberg; G C Cedermark; K Andersson; L Ahrlund-Richter; S Pramana; Y Pawitan; M Nistér; S Nilsson; C Li
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-01-07       Impact factor: 5.554

6.  Dosimetric comparison of intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy in patients with prostate cancer: a meta-analysis.

Authors:  Wenting Ren; Chao Sun; Ningning Lu; Yingjie Xu; Fei Han; Yue Ping Liu; Jianrong Dai
Journal:  J Appl Clin Med Phys       Date:  2016-11-08       Impact factor: 2.102

7.  Feasibility and radiation induced toxicity regarding the first application of transperineal implementation of biocompatible balloon for high dose radiotherapy in patients with prostate carcinoma.

Authors:  Vassilis Kouloulias; Theodoros Kalogeropoulos; Kalliopi Platoni; John Georgakopoulos; George Matsopoulos; Dimitris Chaldeopoulos; Ivelina Beli; Panagiotis Pantelakos; Charalambos Asimakopoulos; John Kouvaris; Nikolaos Kelekis
Journal:  Radiat Oncol       Date:  2013-04-08       Impact factor: 3.481

8.  Impact of Pelvic Radiation Therapy for Prostate Cancer on Global Metabolic Profiles and Microbiota-Driven Gastrointestinal Late Side Effects: A Longitudinal Observational Study.

Authors:  Miguel R Ferreira; Caroline J Sands; Jia V Li; Jervoise N Andreyev; Elena Chekmeneva; Sarah Gulliford; Julian Marchesi; Matthew R Lewis; David P Dearnaley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-02       Impact factor: 7.038

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.